Rapid expansion of Neisseria gonorrhoeae ST7827 clone in Australia, with variable ceftriaxone phenotype unexplained by genotype
Journal of Antimicrobial Chemotherapy · 2023
DOI: 10.1093/jac/dkad221 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2023. Verfasst von S J van Hal und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases and Microbiology, NSW Health Pathology, Royal Prince Alfred Hospital, Sydney, NSW 2050, Australia. Hauptthemen laut MEDLINE: Neisseria gonorrhoeae, Gonorrhea. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
Background
Neisseria gonorrhoeae is identified as a priority pathogen due to its capacity to rapidly develop antimicrobial resistance (AMR). Following the easing of SARS-CoV-2 pandemic travel restrictions across international borders in the state of New South Wales (NSW), Australia, a surge of gonococcal isolates with raised ceftriaxone MIC values were detected.
Methods
All N. gonorrhoeae isolates (n = 150) with increased ceftriaxone MIC values in NSW between 1 January 2021 and July 2022 from males and females from all sites were sequenced.
Results
A new emergence and rapid expansion of an N. gonorrhoeae ST7827 clone was documented within NSW, Australia and provides further evidence of the ability of N. gonorrhoeae to undergo sufficient genomic changes and re-emerge as a geographically restricted subclone. Mapping AMR determinants to MIC results did not reveal any genomic pattern that correlated with MIC values.
Conclusions
The rapid dissemination and establishment of this clone at the population level is a new and concerning demonstration of the agility of this pathogen, and underscores concerns about similar incursions and establishment of MDR clones. Moreover, it is notable that in this context the AMR genotype–phenotype correlates remain unclear, which requires further investigation to enable better understanding of genomic aspects of AMR in N. gonorrhoeae.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases and Microbiology, NSW Health Pathology, Royal Prince Alfred Hospital, Sydney, NSW 2050, Australia.
- Central Clinical School, University of Sydney, Sydney, NSW 2006, Australia.
- UQ Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
- Pathology Queensland Central Laboratory, Queensland Health, Brisbane, Queensland, Australia.
- World Health Organization Collaborating Centre for STI and AMR, New South Wales Health Pathology Microbiology, The Prince of Wales Hospital, Randwick, New South Wales, Australia.
- Communicable Diseases Branch, Health Protection NSW, NSW Health, Sydney, Australia.
ORCID-Profile: S J van Hal
Zitieren
APA
van Hal, S. J., Whiley, D. M., Le, T., Ray, S., Kundu, R. L., Kerr, E., & Lahra, M. M. (2023). Rapid expansion of Neisseria gonorrhoeae ST7827 clone in Australia, with variable ceftriaxone phenotype unexplained by genotype. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkad221
Vancouver
van Hal SJ, Whiley DM, Le T, Ray S, Kundu RL, Kerr E, et al. Rapid expansion of Neisseria gonorrhoeae ST7827 clone in Australia, with variable ceftriaxone phenotype unexplained by genotype. Journal of Antimicrobial Chemotherapy. 2023. doi:10.1093/jac/dkad221
BibTeX
@article{vanHal2023,
author = {van Hal, S J and Whiley, D M and Le, T and Ray, S and Kundu, R L and Kerr, E and Lahra, M M},
title = {Rapid expansion of Neisseria gonorrhoeae ST7827 clone in Australia, with variable ceftriaxone phenotype unexplained by genotype},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2023},
doi = {10.1093/jac/dkad221}
}
EUVIMED